Discovery of an early diagnostic biomarker
Herein we describe the discovery of a small molecule biomarker revealing potential drug targets, and that provides an early diagnostic for NASH by predicting disease development more than 10 years in advance.
Discovery in Action
Enabling early, non-invasive diagnosis of NASHSchedule a Meeting
Nonalcoholic steatohepatitis (NASH) is a disease for which diagnosis has proven to be challenging, typically requiring MRI-based imaging and/or biopsy of the liver, at which point significant organ damage may have already occurred. Sapient’s client was interested in identifying a circulating diagnostic biomarker that can reveal patients with NASH at a very early stage in their disease process. See the discovery findings below.